Biomet/Selective Genetics
This article was originally published in The Gray Sheet
Executive Summary
Biomet makes a $5 mil. upfront equity investment in privately held, San Diego-based Selective Genetics as part of a corporate alliance covering the application of Selective Genetics' Gene Activated Matrix (GAM) and other technologies for orthopedic indications, including spinal fusion, hip fracture repair, tendon and ligament repair, among others. Selective Genetics plans to begin clinical trials in late 1999 or early 2000. Biomet, which gains a worldwide exclusive license to market all covered products under the agreement, also will fund R&D and be responsible for the regulatory process with FDA. The value of the deal could exceed $32 mil., including the initial investment, R&D funding, and "a potential further equity investment," Selective Genetics says. The firm will also receive product sales royalties
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.